These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9150695)

  • 1. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
    Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
    Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing an optimal follow-up strategy based on the natural history of nonfunctioning pituitary adenomas.
    Kim JH; Dho YS; Kim YH; Lee JH; Lee JH; Hong AR; Shin CS
    J Neurosurg; 2019 Aug; 131(2):500-506. PubMed ID: 30215565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients.
    Biermasz NR; Smit JW; Pereira AM; Frölich M; Romijn JA; Roelfsema F
    Pituitary; 2007; 10(3):237-49. PubMed ID: 17541749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report.
    Shiraishi K; Akai T; Tomita T; Hayashi R; Minamisaka T; Kuroda S
    Neuropathology; 2024 Jun; 44(3):247-251. PubMed ID: 38099404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study.
    Zhao R; Fan K; Wan W
    BMC Endocr Disord; 2023 Aug; 23(1):176. PubMed ID: 37587420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone increase by luteinizing hormone-releasing hormone reflects gonadotroph-related characteristics in acromegaly.
    Mitsui Y; Mukai K; Otsuki M; Oshino S; Saitoh Y; Kohara M; Morii E; Fukuhara A; Shimomura I
    Pituitary; 2024 Jun; ():. PubMed ID: 38954291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Connexin 36 Mediated Intercellular Endoplasmic Reticulum Stress Transmission Induces SSTA Resistance in Growth Hormone Pituitary Adenoma.
    Wang Z; Lei Z; Wang Q; Jiang Q; Zhang Z; Liu X; Xing B; Li S; Guo X; Liu Y; Li X; Qi Y; Shu K; Zhang H; Huang Y; Lei T
    Int J Biol Sci; 2024; 20(2):801-817. PubMed ID: 38169563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Treatment of Non-Functioning Pituitary Adenomas.
    Vargas-Ortega G; Gonzalez-Virla B; Romero-Gameros CA
    Arch Med Res; 2023 Dec; 54(8):102917. PubMed ID: 37996269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FSH-producing pituitary neuroendocrine tumor as a cause of ovarian hyperstimulation syndrome.
    Kitamura T; Nanba K; Doi K; Kishimoto N; Abiko K; Kuwahara R; Moriyoshi K; Inoshita N; Tagami T
    Endocrinol Diabetes Metab Case Rep; 2024 Jan; 2024(1):. PubMed ID: 38421932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unravelling pituitary tumours in medically treated patients with acromegaly: the impact of systematic MRI reassessment.
    Atai S; Knudtzon Andersen M; Wiedmann M; Dahlberg D; Øystese KAB; Bollerslev J; Ringstad G; Heck A
    Acta Radiol; 2024 Jul; 65(7):753-758. PubMed ID: 38659302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis.
    Del Corso LM; Mesa Junior CO; Andrade VFC; Fidalski SZK; Boguszewski CL
    Pituitary; 2024 Aug; ():. PubMed ID: 39088137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Imaging of Pituitary Tumors.
    Gillett D; MacFarlane J; Bashari W; Crawford R; Harper I; Mendichovszky IA; Aloj L; Cheow H; Gurnell M
    Semin Nucl Med; 2023 Jul; 53(4):530-538. PubMed ID: 36966020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-function relationship of the pituitary gland in anorexia nervosa and intense physical activity.
    Merabet M; Germain N; Redouté J; Boutet C; Costes N; Ptito M; Galusca B; Schneider FC
    Brain Struct Funct; 2024 Jan; 229(1):195-205. PubMed ID: 38062204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive [
    Veldhuijzen van Zanten SEM; Neggers SJCMM; Valkema R; Verburg FA
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):410-411. PubMed ID: 34223953
    [No Abstract]   [Full Text] [Related]  

  • 16. IMMUNOHISTOCHEMICAL MARKERS AND SPECT/CT SOMATOSTATIN-RECEPTOR (99MTC-TEKTROTYD) UPTAKE IN WELL AND MODERATELY DIFFERENTIATED NEUROENDOCRINE TUMORS.
    Bădan MI; Piciu D
    Acta Endocrinol (Buchar); 2022; 18(4):523-530. PubMed ID: 37152876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.
    Peverelli E; Treppiedi D; Mangili F; Catalano R; Spada A; Mantovani G
    Nat Rev Endocrinol; 2021 Sep; 17(9):560-571. PubMed ID: 34194011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a
    Boertien TM; Drent ML; Booij J; Majoie CBLM; Stokkel MPM; Hoogmoed J; Pereira A; Biermasz NR; Simsek S; Groote Veldman R; Tanck MWT; Fliers E; Bisschop PH
    BMJ Open; 2020 Aug; 10(8):e038250. PubMed ID: 32792446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.
    Paragliola RM; Corsello SM; Salvatori R
    Pituitary; 2017 Feb; 20(1):109-115. PubMed ID: 27778296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.
    Kiseljak-Vassiliades K; Xu M; Mills TS; Smith EE; Silveira LJ; Lillehei KO; Kerr JM; Kleinschmidt-DeMasters BK; Wierman ME
    Mol Cell Endocrinol; 2015 Dec; 417():73-83. PubMed ID: 26391562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.